• Onset: typically nothing acute. Some users report a mild peripheral warmth (hand/foot warming) within days — consistent with mild peripheral vasodilation. Cognitive effects, when they occur, emerge over 4-6 weeks and stabilize by ~12 weeks.
• Week 1-2: generally nothing felt. Some users report mild lightheadedness or slight headache (likely mild vasodilation in cerebral vessels).
• Week 4-8: subset of users (especially older or those with subclinical vascular issues) report subjectively "clearer head," better word retrieval, less mental fog. Younger healthy users typically report nothing.
• Week 8-12: plateau of any subjective effect.
• Bleeding signs: the watch period — easy bruising, prolonged bleeding from minor cuts, gum bleeding when brushing, frequent nosebleeds. These are dose-dependent and mostly emerge in the stacking-with-NSAIDs/SSRIs/anticoagulants context.

• Tolerance: none documented at standard doses. Mechanism is structural / hemorheological / direct-scavenging — not receptor-occupancy-driven. Long-term users (5+ years in GEM) showed no loss of effect or escalation of dose required.
• Cycling: not required for tolerance reasons. Some practitioners cycle off for 2-4 weeks every 6 months to re-baseline; not validated.
• Discontinuation kinetics: PAF antagonism reverses with platelet turnover (~7-10 day half-life pool — by day 7 essentially baseline; by day 14 fully). Vasodilatory and antioxidant effects taper within days.
• Stop protocol pre-surgery: ≥7 days minimum, 14 days conservative. Resume only ≥48 hr after confirmed hemostasis.

Synergistic with

• Citicoline (CDP-choline): ✅ Different mechanisms (cholinergic substrate vs cerebrovascular flow + antioxidant). Rationale for stacking exists in dementia / vascular cognitive impairment populations. Not particularly synergistic in healthy users in this archetype.
• Vinpocetine: ✅ Both target cerebrovascular flow (vinpocetine via PDE1 inhibition + Na+ channel blockade); commonly co-formulated in old-school nootropic stacks. Both share the antiplatelet caveat; stacking amplifies bleeding-risk concern.
• Bacopa monnieri: ✅ Mechanistically orthogonal (BDNF + cholinergic vs flow + PAF). Plausible stack for cognitive-aging users; not particularly compelling for healthy young adults.
• Rhodiola rosea: ✅ Mostly orthogonal; both are botanical adaptogens with cardiovascular and cognitive signals. Stack-safe.
• DHA / omega-3: ⚠ Mechanistically clean (different pathways) but omega-3 has a mild antiplatelet effect of its own; combined antiplatelet load increases. Manageable at standard doses; flag for users on anticoagulants or aspirin.

Avoid stacking with

• Warfarin: ❌ Multiple case reports of bleeding (intracerebral, subdural, GI). Contraindicated in routine practice.
• Aspirin / DAPT (dual antiplatelet therapy after stent): ❌ Additive antiplatelet via PAF mechanism distinct from COX-1 / P2Y12. Bleeding risk meaningfully elevated.
• Clopidogrel / prasugrel / ticagrelor: ❌ Same logic as aspirin.
• DOACs (apixaban, rivaroxaban, dabigatran, edoxaban): ❌ Additive bleeding risk; case reports exist.
• NSAIDs (ibuprofen, naproxen, ketorolac, diclofenac): ❌ Additive antiplatelet + GI bleeding risk. Particularly relevant for an MMA athlete using ibuprofen post-training — the most common real-world problematic combination.
• SSRIs (sertraline, fluoxetine, paroxetine, escitalopram): ❌ SSRIs reduce platelet serotonin uptake → mild antiplatelet effect of their own. Combined with Ginkgo, bleeding risk rises (case reports of GI bleed, easy bruising). Manageable but worth flagging for users on SSRIs.
• MAOIs (phenelzine, tranylcypromine, selegiline): ⚠ Theoretical additive MAO inhibition; clinical signal weak but flagged.
• Anticonvulsants (especially in valproate-controlled epilepsy): ❌ Possible seizure-threshold lowering in poorly-standardized products. Hard-block in seizure history.
• Trazodone: ⚠ Case report of coma in elderly patient on trazodone + Ginkgo. Mechanism unclear; flag.

Neutral / safe co-administration

• Most V4 stack items: NAC, magnesium glycinate, magnesium L-threonate, creatine, vitamin C, D3+K2, beta-alanine, glycine, taurine, astaxanthin.
• ALCAR, alpha-GPC.
• L-theanine.

• CYP450 effects: Ginkgo is a mild inhibitor of CYP2C19 at higher doses (one of few clinically relevant CYP signals — affects warfarin, phenytoin, diazepam, omeprazole, voriconazole). Inhibition of CYP2C9, CYP3A4, CYP1A2 is variable across studies and probably small at supplement doses.
• P-glycoprotein: Mild inhibition reported; may increase exposure of P-gp substrates (digoxin, talinolol, fexofenadine).
• Warfarin / anticoagulants: Multiple reported interactions (some via PAF, some via CYP2C9 modulation). Contraindicated in routine combined use.
• Phenytoin / valproate: Lower seizure threshold + CYP2C19 inhibition risk. Hard-flag.
• Trazodone: Case report of coma; flag.
• Antidiabetic drugs (sulfonylureas, insulin): Mild effects on glucose handling reported; clinical magnitude small.
• Buspirone, MAO inhibitors: Theoretical serotonergic / monoaminergic additivity; clinical signal weak.

Ginkgo pharmacogenomics is thinly studied vs. CYP-metabolized pharmaceuticals. Main signals:

• CYP2C19 polymorphism — Ginkgo is a CYP2C19 inhibitor. CYP2C19 *2 / *3 poor metabolizers may have amplified effect on co-administered substrates (phenytoin, voriconazole, clopidogrel-active-metabolite). For a user in this archetype: when 23andMe results land, check CYP2C19 status if Ginkgo is ever considered.
• CYP2C9 polymorphism — relevant for warfarin-Ginkgo interaction magnitude; not directly relevant to a healthy user in this archetype.
• APOE genotype — some animal data suggest APOE4 carriers may be more vasoprotection-responsive to Ginkgo flavonoids; clinical confirmation thin.
• No actionable pharmacogenomic signal for Ginkgo itself in healthy young users.

Recommendation for users in this archetype: skip. If a Ginkgo trial is ever justified (vascular or peripheral indication), use Nootropics Depot 240 mg or Nature's Way Ginkgold at 120-240 mg/day. Avoid generic Ginkgo without published 24/6 standardization and <5 ppm ginkgolic acid spec.

Total cost estimate: $10-30/month at standard doses. Cheap; not the limiting factor.

Form note: Always look for 24% flavone glycosides + 6% terpene lactones + <5 ppm ginkgolic acids. Whole-leaf or non-standardized "Ginkgo biloba" capsules without those specs are not equivalent to clinical-trial extracts.

Baseline (before starting)

• Subjective cognitive baseline — structured ratings on memory, word retrieval, mental clarity. Useful for slow-onset compounds.
• CBC + platelet count — baseline before initiating any antiplatelet-active compound.
• PT/INR — only if any anticoagulant context exists.
• Resting BP — Ginkgo can mildly lower BP; relevant in already-low-BP athletes.
• Lipid panel + hs-CRP — general baseline; vascular markers.
• CMP (liver function) — rare hepatotoxicity baseline.

During use

• Subjective cognitive tracking — weeks 0, 4, 8, 12. Focus on word retrieval, mental clarity, peripheral warmth. For users in this archetype expect minimal acute change.
• Bleeding signs — easy bruising, gum bleed when brushing, prolonged bleeding from minor cuts, nosebleeds. Weekly self-check.
• BP monitoring — monthly if baseline already low.
• PFA-100 / platelet function assay — only if any concern about additive antiplatelet effect (not routinely needed).
• INR if on warfarin — weekly during initiation if combination is unavoidable (better: avoid combination).

Post-cycle (if discontinuing)

• Bleeding-time normalization — completes within 7-14 days post-cessation.
• Subjective baseline check at 4-week washout — gauges how much benefit was Ginkgo-dependent.